Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
WGc-043 by Chengdu WestGene Biopharma for Epstein–Barr Virus (HHV-4) Infections: Likelihood of Approval
WGc-043 is under clinical development by Chengdu WestGene Biopharma and currently in Phase I for Epstein–Barr Virus (HHV-4) Infections. According...